MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Eli Lilly and Co.

Cerrado

SectorSalud

737.25 -6.48

Resumen

Variación precio

24h

Actual

Mínimo

736.69

Máximo

747.36

Métricas clave

By Trading Economics

Ingresos

7.8B

8.8B

Ventas

2.1B

14B

P/B

Media del Sector

70.41

63.778

BPA

5.32

Rentabilidad por dividendo

0.73

Margen de beneficio

65.172

Empleados

47,000

EBITDA

1.2B

6.1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+41.41% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.73%

2.39%

Próximas Ganancias

1 may 2025

Próxima Fecha de Ex Dividendo

14 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-43B

742B

Apertura anterior

743.73

Cierre anterior

737.25

Noticias sobre sentimiento de mercado

By Acuity

37%

63%

114 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Eli Lilly and Co. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

4 abr 2025, 22:38 UTC

Acciones populares

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 abr 2025, 23:15 UTC

Principales Movimientos del Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2 abr 2025, 16:53 UTC

Principales Noticias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1 abr 2025, 22:31 UTC

Principales Noticias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 abr 2025, 21:47 UTC

Principales Noticias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19 mar 2025, 15:54 UTC

Principales Noticias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14 mar 2025, 09:30 UTC

Principales Noticias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28 feb 2025, 12:00 UTC

Principales Noticias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 feb 2025, 15:14 UTC

Principales Noticias

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26 feb 2025, 14:30 UTC

Principales Noticias

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10 feb 2025, 12:00 UTC

Principales Noticias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 feb 2025, 10:30 UTC

Principales Noticias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 feb 2025, 16:16 UTC

Principales Noticias
Ganancias

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 feb 2025, 14:56 UTC

Ganancias

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6 feb 2025, 14:32 UTC

Charlas de Mercado
Ganancias

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6 feb 2025, 13:18 UTC

Principales Noticias
Ganancias

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

6 feb 2025, 12:24 UTC

Ganancias

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

6 feb 2025, 12:01 UTC

Ganancias

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

6 feb 2025, 11:49 UTC

Ganancias

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

6 feb 2025, 11:48 UTC

Ganancias

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

6 feb 2025, 11:47 UTC

Ganancias

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

6 feb 2025, 11:46 UTC

Ganancias

Eli Lilly 4Q Gross Margin 82.2% >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly 4Q Humalog Rev $619.9M >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly Sees FY Rev $58B-$61B >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly 4Q Net $4.41B >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly 4Q EPS $4.88 >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

6 feb 2025, 11:45 UTC

Ganancias

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

Comparación entre iguales

Cambio de precio

Eli Lilly and Co. Esperado

Precio Objetivo

By TipRanks

41.41% repunte

Estimación a 12 meses

Media 1,043.87 USD  41.41%

Máximo 1,190 USD

Mínimo 900 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Eli Lilly and Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

18

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 825.32Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

114 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.